Literature DB >> 25096510

Association of peroxisome proliferator-activated receptorγ gene Pro12Ala and C161T polymorphisms with cardiovascular risk factors in maintenance hemodialysis patients.

Feng Liu1, Xiaobin Mei, Yingying Zhang, Hualin Qi, Jun Wang, Yi Wang, Wei Jiang, Xintian Zhang, Haidong Yan, Shougang Zhuang.   

Abstract

The Pro12Ala and C161T polymorphisms in peroxisome proliferator-activated receptor γ (PPARγ) have been shown to be associated with carotid artery atherosclerosis. It remains unclear whether these two polymorphisms are associated with risk factors for cardiovascular disease (CVD) in hemodialysis (HD) patients. Therefore, the PPARγ genotypes in 99 HD patients and 149 controls were determined, and clinical characteristics among the different genotypes were compared. We found that the frequency of the Pro12Ala and C161T polymorphisms in HD patients was similar to that in healthy controls, but C161T polymorphism and T allele frequencies in HD patients with CVD were lower than that in HD patients without CVD. Carotid artery plaque (CAP) and carotid intima-media thickness (CIMT) in HD patients with CT + TT or Pro12Ala genotypes were also less than that in patients with CCor Pro12Pro genotypes, respectively. HD patients with CT + TT genotype had lower serum C reactive protein (CRP) levels, as well as higher triceps skin fold (TSF) thickness, mid arm circumference (MAC) and mean mid arm circumference (MMAC) than HD patients with CC genotype (P < 0.05). Moreover, CIMT of the Pro12Ala-CT161 subgroup was less than the Pro12Pro-CC161 and Pro12Pro-CT161 subgroup, and, CAP amounts of the Pro12Ala-CT161 subgroup was less than the Pro12Pro-CC161 subgroup. Our results indicate that the Pro12Ala and C161T polymorphisms were associated with some important risk factors for CVD in HD patients in the Han Chinese population.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25096510     DOI: 10.1007/s11033-014-3645-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  36 in total

Review 1.  Atherogenesis in renal patients: a model of vascular disease?

Authors:  Georgios Efstratiadis; Konstantinos Tziomalos; Dimitri P Mikhailidis; Vasilios G Athyros; Apostolos Hatzitolios
Journal:  Curr Vasc Pharmacol       Date:  2008-04       Impact factor: 2.719

Review 2.  Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective.

Authors:  Rupal Dumasia; Kim A Eagle; Eva Kline-Rogers; Niquole May; Leslie Cho; Debabrata Mukherjee
Journal:  Curr Drug Targets Cardiovasc Haematol Disord       Date:  2005-10

Review 3.  Role of peroxisome proliferator-activated receptor-γ in atherosclerosis: an update.

Authors:  Nanping Wang; Ruiying Yin; Yan Liu; Guangmei Mao; Fang Xi
Journal:  Circ J       Date:  2011-02-11       Impact factor: 2.993

4.  Peroxisome proliferator-activated receptor gamma C161-->T polymorphism and coronary artery disease.

Authors:  X L Wang; J Oosterhof; N Duarte
Journal:  Cardiovasc Res       Date:  1999-12       Impact factor: 10.787

Review 5.  The nuclear receptor PPARgamma - bigger than fat.

Authors:  S A Kliewer; T M Willson
Journal:  Curr Opin Genet Dev       Date:  1998-10       Impact factor: 5.578

Review 6.  The meta-analysis of the association of PPARG P12A, C161T polymorphism and coronary heart disease.

Authors:  Saidan Ding; Leping Liu; Qï-Chuan Zhuge; Zhen Yu; Xing Zhang; Jieya Xie; Weilong Hong; Silu Wang; Yunxiu Yang; Bicheng Chen
Journal:  Wien Klin Wochenschr       Date:  2012-09-18       Impact factor: 1.704

7.  Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin.

Authors:  A Werman; A Hollenberg; G Solanes; C Bjorbaek; A J Vidal-Puig; J S Flier
Journal:  J Biol Chem       Date:  1997-08-08       Impact factor: 5.157

8.  Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study.

Authors:  Deepak L Bhatt; Derek P Chew; Cindy Grines; Debabrata Mukherjee; Massoud Leesar; Ian C Gilchrist; John C Corbelli; James C Blankenship; Avichai Eres; Steven Steinhubl; Walter A Tan; Jon R Resar; Amjad AlMahameed; Ahmed Abdel-Latif; W H Wilson Tang; H Wilson Tang; Danielle Brennan; Ellen McErlean; Stanley L Hazen; Eric J Topol
Journal:  Am Heart J       Date:  2007-07       Impact factor: 4.749

9.  The C161T polymorphism in the peroxisome proliferator-activated receptor gamma gene (PPARγ) is associated with risk of coronary artery disease: a meta-analysis.

Authors:  Zhijun Wu; Yuqing Lou; Wei Jin; Yan Liu; Lin Lu; Guoping Lu
Journal:  Mol Biol Rep       Date:  2012-12-25       Impact factor: 2.316

10.  The association of Pro12Ala polymorphism in PPARgamma2 with lower carotid artery IMT in Japanese.

Authors:  E Iwata; I Yamamoto; T Motomura; S Tsubakimori; S Nohnen; M Ohmoto; T Igarashi; J Azuma
Journal:  Diabetes Res Clin Pract       Date:  2003-10       Impact factor: 5.602

View more
  5 in total

1.  G Allele of the rs1801282 Polymorphism in PPARγ Gene Confers an Increased Risk of Obesity and Hypercholesterolemia, While T Allele of the rs3856806 Polymorphism Displays a Protective Role Against Dyslipidemia: A Systematic Review and Meta-Analysis.

Authors:  Shujin Li; Chuan He; Haiyan Nie; Qianyin Pang; Ruixia Wang; Zhifu Zeng; Yongyan Song
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

2.  Gene-gene interaction between PPARG and CYP1A1 gene on coronary artery disease in the Chinese Han Population.

Authors:  Xiaojiang Zhang; Shuzheng Lv; Chengjun Guo; Conghong Shi; Yunpeng Chi; Lin Zhao; Guozhong Wang; Zhisheng Wang
Journal:  Oncotarget       Date:  2017-05-23

3.  PPARG Pro12Ala Polymorphism with CKD in Asians: A Meta-Analysis Combined with a Case-Control Study-A Key for Reaching Null Association.

Authors:  Hsiang-Cheng Chen; Wei-Teing Chen; Tzu-Ling Sung; Dung-Jang Tsai; Chin Lin; Hao Su; Yuh-Feng Lin; Hung-Yi Chiu; Sui-Lung Su
Journal:  Genes (Basel)       Date:  2020-06-26       Impact factor: 4.096

4.  The Effect of PPARγ rs1801282 Variant on Mortality Risk Among Asians With Chronic Kidney Disease: A Cohort Study and Meta-Analysis.

Authors:  Wei-Teing Chen; Chih-Chien Chiu; Dung-Jang Tsai; Pi-Shao Ko; Meng-Chang Lee; Hsiao-Ting Lin; Ying-Kai Chen; Wen Su; Yuh-Feng Lin; Sui-Lung Su
Journal:  Front Genet       Date:  2022-02-21       Impact factor: 4.599

Review 5.  PPARγ Gene Polymorphisms, Metabolic Disorders, and Coronary Artery Disease.

Authors:  Yongyan Song; Shujin Li; Chuan He
Journal:  Front Cardiovasc Med       Date:  2022-03-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.